Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580592 | 0.90 | SCN9A (0.44) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL3585372 | 0.88 | PRKCA (0.51) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL3085929 | 0.88 | SCN9A (0.43) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL3084872 | 0.87 | SCN9A (0.45) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL3073410 | 0.84 | SCN9A (0.42) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL772587 | 0.83 | SCN9A (0.47) | SCN9APRKCAMMP12NR1I2ALDH1A1 | |
| SCHEMBL14253376 | 0.83 | PRKCA (0.46) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL3659420 | 0.83 | PRKCA (0.46) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL4829851 | 0.83 | PRKCA (0.46) | SCN9APRKCAMMP12NR1I2KCNH2 | |
| SCHEMBL771196 | 0.83 | SCN9A (0.49) | SCN9APRKCAMMP12NR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662809-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-02-16 | — | — | US | disclosed |
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, HAVCR2 | SCN9A 3739/4885PRKCA 4232/4885MMP12 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.